{rfName}
Va

Indexed in

License and use

Citations

23

Altmetrics

Grant support

Part of the work was funded by the public Catalan Health Department, Generalitat de Catalunya, Departament de Salut (PERIS 2019-2021), resolution SLT/3104/2018 (G.J.); and Instituto de Salud Carlos III (PI17/00732; PI PI19/01867). This work was co-funded by European Regional Development Fund/European Social Fund; A way to make Europe/Investing in your future). Part of the work was also funded by Premi Fi de Residencia Emili Letang from Hospital Clinic Barcelona.

Analysis of institutional authors

Bayó CAuthorJung GAuthorEspañol-Rego MAuthorBalaguer FCorresponding AuthorBenitez-Ribas DCorresponding Author
Share
Publications
>
Review

Vaccines for Non-Viral Cancer Prevention

Publicated to:International Journal Of Molecular Sciences. 22 (20): 10900- - 2021-10-01 22(20), DOI: 10.3390/ijms222010900

Authors: Bayo, Cristina; Jung, Gerhard; Espanol-Rego, Marta; Balaguer, Francesc; Benitez-Ribas, Daniel

Affiliations

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Department of Gastroenterology, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Hospital Clínic Barcelona, University of Barcelona, 08036 Barcelona, Spain. - Author
Department of Immunology, Fundació Clínic per la Recerca Biomèdica (FCRB), Hospital Clínic Barcelona, University of Barcelona, 08036 Barcelona, Spain. - Author
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol, IDIBAPS Inst Invest Biomed August Pi & Sunyer,Hos, Barcelona 08036, Spain - Author
Univ Barcelona, Dept Immunol, FCRB, Hosp Clin Barcelona, Barcelona 08036, Spain - Author

Abstract

Cancer vaccines are a type of immune therapy that seeks to modulate the host's immune system to induce durable and protective immune responses against cancer-related antigens. The little clinical success of therapeutic cancer vaccines is generally attributed to the immunosuppressive tumor microenvironment at late-stage diseases. The administration of cancer-preventive vaccination at early stages, such as pre-malignant lesions or even in healthy individuals at high cancer risk could increase clinical efficacy by potentiating immune surveillance and pre-existing specific immune responses, thus eliminating de novo appearing lesions or maintaining equilibrium. Indeed, research focus has begun to shift to these approaches and some of them are yielding encouraging outcomes.

Keywords
cancerclinical-trialcolorectal-cancerdendritic cellsdnaimmunogenicitylynch syndromemicrosatellite instabilityneoantigen vaccinephase-i trialpreventionCancerCancer vaccinesCell lung-cancerDendritic cellsHumansLynch syndromeNeoplasm stagingNeoplasmsPrecancerous conditionsPreventionTumor microenvironmentVaccines

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal Of Molecular Sciences due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 69/297, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biochemistry & Molecular Biology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.39, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-14, the following number of citations:

  • WoS: 8
  • Scopus: 9
  • Europe PMC: 6
  • OpenCitations: 6
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-14:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 22.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 22 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.2.
  • The number of mentions on the social network X (formerly Twitter): 7 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Bayo Llorens, Cristina) and Last Author (Benítez Ribas, Daniel).

the authors responsible for correspondence tasks have been Balaguer Prunes, Francesc and Benítez Ribas, Daniel.